PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab with chemotherapy in triple negative breast cancer (TNBC)

BACKGROUND: In both the IMpassion 130 trial in the metastatic setting and in Keynote 522 in the neoadjuvant setting, triple negative breast cancer (TNBC) patients showed benefit from PD-1 axis immunotherapy. Here, we assess PD-L1 expression on both tumor and immune cells using quantitative immunoflu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Ahmed, Fahad Shabbir, Gaule, Patricia, McGuire, John, Patel, Katir, Blenman, Kim, Pusztai, Lajos, Rimm, David L.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7572612/
https://ncbi.nlm.nih.gov/pubmed/32709714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-1303
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares